PLANFORGE
14.12.2023 14:31:38 CET | Business Wire | Press release
Medium-sized and larger organizations often struggle to innovate despite a wealth of great ideas in their employee base. The challenge is that these ideas never reach the decision-makers responsible for driving the creative process. Planforge aims to address this problem with Release 24 of its hybrid project and portfolio management (PPM) software by introducing a new option for integrated innovation management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231214791999/en/
Planforge's idea bubble chart with configurable evaluation criteria (Graphic: Business Wire)
Supporting the Modern Idea Management Process
Planforge's new Idea Management Option (IMO) is an additional module designed to support all major steps of the modern innovation management process, including:
- Enabling every employee to easily submit new ideas
- Supporting ideas as distinct, reportable business objects
- Defining a separate set of evaluation criteria for ideas
- Allowing idea management across all portfolio levels
- Providing tabular and graphical analytical capabilities (based on configurable bubble charts).
"Driving continuous and sustainable innovation is a major challenge for many larger organizations," says Gerald Aquila, Founder & CEO of Planforge. "Our new Idea Management Option keeps creativity flowing by making it easy for employees to submit new ideas and providing decision-makers with the right tools to select the best ideas."
From Idea to Strategy and Implementation
In Planforge, idea management is deeply interlinked with other capabilities of the PPM platform. For instance, ideas selected for prototyping or implementation can be linked to one or more projects or SAFe Epics. These projects or Epics, in turn, can be linked to key results of strategic objectives (OKRs), ensuring that new features and developments are aligned with the overall organizational strategy.
Although not available from the start, an integration with Jira for idea-collection is already planned for the near future. A logical consequence, as Planforge is well known for its bi-directional Jira integration for project management and SAFe workflows.
Availability
Version 24, including the Idea Management Option (IMO), is now available at www.planforge.io. Planforge is free for up to four users. Larger teams can test the hybrid PPM software in a free trial for 30 days. For more information or to test integrations with Jira or SAP, contact the Planforge sales team at info@planforge.io.
About Planforge
Planforge is a leading provider of hybrid program and portfolio management software. By integrating cross-functional processes from Jira and enterprise agile planning (SAFe) to resource management, the web-based PPM solution closes the gaps between information silos. Planforge empowers your organization to adapt to changing environments faster, turn strategy into action, and make better value-based decisions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231214791999/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom